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ABSTRACT
Objectives: The use of laparoscopy to treat malignant
hematological diseases is not completely accepted. Our
aim was to analyze operative and postoperative results of
laparoscopic splenectomy performed for benign versus
malignant hematological disorders.
Methods: Between 1994 and 2003, 76 consecutive pa-
tients underwent laparoscopic splenectomy. The first 38
cases were performed by using an anterior approach,
whereas in the remaining 38 cases a semilateral position
was used.
Results: Baseline characteristics showed that patients
with malignant diseases were significantly older (56.9 vs
32.6 years, P0.001). Seventy-two (94.7%) procedures
were completed laparoscopically. Conversion was re-
quired in 4 cases (5.2%). Mean operative time was 138.5
minutes for benign and 151.0 minutes for malignant dis-
eases, (P0.05, ns). The hand-assisted technique was
used in 3 patients with massive splenomegaly. Pathologic
features showed that spleen volume was higher in pa-
tients with malignant diseases (mean interpole diameter
18.1 cm vs 13.7 cm, P0.001). Massive splenomegaly
(interpole diameter over 20 cm, weight over 1000 g) was
present in 13 patients (17.1%); 9 had malignant diseases.
Overall perioperative mortality was 1.3% and major post-
operative complications occurred in 6 patients (7.8%).
Postoperative splenoportal partial thrombosis was identi-
fied in 9.7% of patients.
Conclusions: Laparoscopic splenectomy is a well-ac-
cepted, less-invasive procedure for hematological disor-
ders. Neoplastic diseases or splenomegaly, or both, do not
seem to limit the indications for a minimally invasive
approach after the learning curve.
Key Words: Laparoscopic splenectomy, Malignant, Be-
nign, Hematological diseases.
INTRODUCTION
The first laparoscopic splenectomies (LS) were performed
more than a decade ago by Delaitre1 in France (1991),
Carrol2 in the USA (1992), and Poulin3 in Canada (1992).
Many other experiences have been reported since then,
and indications for surgery have been expanded to in-
clude adults and children with nontraumatic diseases.4–6
Less surgical trauma and intraoperative blood loss, early
hospital discharge, rapid return to normal activities, and
better cosmetics have been proposed as major advantages
of LS in adult.1–3
The most frequent indication for LS is immune thrombo-
cytopenic purpura (ITP),7–10 followed by hereditary
spherocytosis and autoimmune hemolytic anemia. Several
studies have demonstrated the feasibility and safety of the
laparoscopic approach also in cases of massive spleno-
megaly (interpole diameter 20 cm, spleen weight1000
g).11,12
Successful experiences with LS have been reported as well
in patients with hematological malignancies.7,13,14 How-
ever, concerns about technical difficulties have limited
this approach in cases of malignancies, and only limited
series have been reported. It is a common opinion that in
cases of lymphomas, large spleen, perisplenitis, and hilar
lymphadenopathy may negatively affect manipulation
and removal of the spleen. Primary lymphomas, spleno-
megaly, staging (in select cases), restaging after radio/
chemotherapy, and focal lesions (suspected recurrence)
are reported as indications for LS.15
The aims of the present study were to analyze the results
in 76 consecutive patients (adults and children) with ei-
ther benign or malignant diseases and to evaluate the
benefits of laparoscopy in patients with lymphomas and
other hematological malignancies.
METHODS
Our database was reviewed for patients who had under-
gone laparoscopic splenectomy. Between May 1994 and
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SCIENTIFIC PAPERDecember 2003, 76 consecutive patients were operated
on for hematological benign and malignant diseases. The
preoperative workup included routine blood tests, chest
x-ray, and electrocardiography. In all patients, additional
diagnostic examinations for surgical purposes were ob-
tained no more than 2 weeks before surgery, ie, abdom-
inal ultrasound with measurement of the maximum inter-
pole diameter of the spleen and computed tomography
scan or magnetic resonance imaging of the abdomen in
case of suspected hematological malignancies. The last 41
patients underwent routine pre- and postoperative (7th
day) ultrasound color Doppler examination of the splenic
vessels to identify postoperative splenic or portal throm-
bosis, or both. At least 1 week before surgery, all patients
were vaccinated for pneumococcus (Pneumovax, Merck
& Co, Inc, Whitehouse Station, NJ, USA), Haemophilus
influenzae (Prohibit, Connaught Laboratories, Inc, Swift-
water, USA) and meningococcus (Meningokokken, Baxter
GmbH, Deutschland). All patients received intravenous
antibiotic prophylaxis (piperacillin 4 g) 2 hours before
surgery.
Patients with malignant and benign disease were com-
pared for the following characteristics: age, sex, operative
time (measured from incision to skin closure), transfu-
sions, weight, and interpole diameter (ID) of the spleen,
intraoperative complications, causes of conversion to
open surgery, postoperative mortality, 30-day morbidity,
reoperations, and length of hospital stay.
Specific late complications related to laparoscopy and to
the histopathological diagnosis were also taken into account.
Massive splenomegaly was defined as splenic interpole di-
ameter (ID) 20 cm or as splenic weight 1000 g.
Values are expressed as mean  standard deviation
(MSD). All continuous variables were compared using
the Student t test, and proportions were compared using
the chi square test or Fisher’s exact test. P0.05 was consid-
ered statistically significant (confidence interval 95%).
Surgical Approach
Anterior Approach
In the first 38 consecutive cases (May 1994 through Feb-
ruary 1999), an anterior approach was adopted. The pa-
tient was placed in the lithotomy position, with the sur-
geon standing between the legs of the patient, and the
assistant holding the camera on his right. Pneumoperito-
neum was created with a Veress needle, in the majority of
the cases inserted at the left subcostal margin. A 30-degree
laparoscope was routinely used. The first 10-mm to
12-mm port was inserted in the umbilicus or at the left
subcostal margin (depending on the spleen size and body
mass index). A subxiphoid 5-mm port and a 10-mm to
12-mm left flank port were inserted. The position of the
fourth port was based on the size of the spleen, but
generally was between the xiphoid and camera port.
The first step of the procedure consists of the exploration
of the abdominal cavity looking for accessory spleens in
case of benign diseases or for lymphadenopathy and he-
patic lesions in malignancies. In case of massive spleno-
megaly, to reduce the spleen size and the risk of bleeding,
the main trunk of the splenic artery on the superior edge
of the body of the pancreas was clipped. Exposure of the
spleen was facilitated by the reverse Trendelenburg posi-
tion and right-side rotation. Mobilization of the spleen
began at the inferior pole dividing the spleno-colic liga-
ment. Then the spleno-gastric ligament and the short gas-
tric vessels were divided using clips or Harmonic scalpel
(Ultracision, Ethicon Endo-Surgery, Cincinnati, OH, USA).
The spleen mobilization was completed along its lateral
and superior attachment with the diaphragm. The main
splenic vessels were clipped or stapled using linear endo-
scopic cutter with vascular cartridge (ETS 30/45–2.5, Ethi-
con or Endo-Gia II 30/45–2.5, US Surgical, Tyco, Norwalk,
CT, USA). A retrieval bag (Endocatch II, Tyco) was in-
serted percutaneously at the site of the left flank port, and
the spleen was grasped and packed into the plastic bag. In
case of benign diseases, the spleen was morcellated into
the plastic bag before extraction. When malignancy was
suspected, the spleen was introduced into the bag and
divided into large pieces (3 cm) before retrieval through
the enlarged port site.
Semilateral Approach
Since February 1999, a semilateral position with the left
side elevated at 45 degrees and a reverse Trendelenburg
has been used. This position has the advantage of splenic
dislocation due to gravity (ie, medial retraction of the
spleen), and it also allows a more comfortable access in
case of hand-assistance. The same position of the surgical
team is used as above. LS is typically a 2-surgeon opera-
tion, both facing the patient’s abdomen and a single mon-
itor over the patient’s left shoulder for in-line operating.
Three or 4 ports along the left subcostal margin are used.
The position of the most lateral port must be 4cm to 5cm
below the inferior tip of the spleen to manage large
organs. Proceeding from the lower pole, the peritoneal
attachments are sharply divided using the Harmonic scal-
pel. After the mobilization of the inferior pole, the dissec-
tion proceeds lateral to medial approaching the short
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endoscopic stapler with vascular cartridge (Endo-Gia II
45-2.5, US Surgical), taking care to preserve the tail of the
pancreas. The mobilization is completed by dividing the
attachment of the superior pole from the stomach and
diaphragm.
In select cases of massive spleen, a hand-assisted proce-
dure (without specific device) was adopted, with the sur-
geon’s left hand through an enlarged umbilical incision (7
cm).
RESULTS
From May 1994 to December 2003, 76 consecutive pa-
tients (M33, F43), with a mean age of 40.220.9 years
(range, 4 to 73) underwent LS. Eleven (14.4%) patients
(M5, F6) were younger than 18 years of age (mean
age, 10.85.4). Mean operative time was 143.642.0 min-
utes (range, 60 to 240), and mean hospital stay was
5.53.2 days (range, 2 to 24). Baseline clinical and oper-
ative characteristics for patients with benign diseases
(groupI-5 2patients) and malignant diseases (group II -
24 patients) are shown in Table 1. Surgical indications are
summarized in Table 2.
Seventy-two (94.7%) of 76 procedures were completed
laparoscopically. Intraoperative bleeding from major
splenic vessels occurred in 3 patients: 2 in group I (3.8%)
and 1 in group II (4.1%) with Hodgkin’s disease (HD) for
failure of the endoscopic linear cutter (EndoGIA,
302.5mm, vascular cartridge). Conversion was required
to control splenic bleeding in 1 patient from group I.
Three conversions were necessary for massive spleno-
megaly (ID 22 cm) in a patient with pancytopenia and a
large incisional hernia; multiple splenic abscesses with
perisplenitis in a patient with non-Hodgkin’s lymphoma
(NHL); marked splenomegaly (ID 25 cm) in 1 patient with
NHL. Conversion rate was higher, although not statisti-
cally significant (Fisher’s exact test, F  0.41), in cases of
LS performed for malignant (8.3%) versus benign diseases
(3.8%).
Postoperative data are reported in Table 3. Patients re-
ceived a soft diet on the second postoperative day. Major
postoperative complications occurred in 6 patients (7.9%).
Three patients had left subphrenic abscesses (2 of group
II), successfully treated by percutaneous drainage. One
group I patient had hemoperitoneum on the first postop-
erative day, successfully treated by percutaneous emboli-
zation of the splenic artery. Two patients were reoperated
Table 1.






Age (years) 32.619.0 56.914.0 0.001
Operative time (minutes) 138.543.5 15134.5 NS
Intraoperative
complications
2 (3.8%) 1 (4.2%) NS, 0.9
Conversion 2 (3.8%) 2 (8.3%) NS, 0.4
Mean ID* (cm) 13.73.2 18.15.8 0.001
Massive splenomegaly ID*
20 cm
4 (7.6%) 9 (37.5%) —
*IDsplenic interpole diameter.
Table 2.








Spherocytosis 17 Splenomegaly: primary
diagnosis
8











4 Splenic lesions: primary
diagnosis
5
Splenic cyst 2 Splenic lesions: suspicion
of recurrence
2







Characteristics Group I Group II P
Transfusions 2 (3.8%) 2 (8.3%) NS, 0.4
Complications 3 (5.7%) 3 (12.5%) NS, 0.3
Postoperative splenoportal
vein thrombosis
2 (3.8%) 2 (8.3%) NS, 0.4
Hospital stay (days) 5.5 (2–11) 5.9 (3–10) NS, 0.3
Reoperations 1 (1.9%) 1 (4.1%) NS, 0.1
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fistula (group II). The last patient died of a pulmonary
embolism 30 days after surgery.
Control of the main vessels was obtained either with clips
(60%), stapler (30%) or Endoloop (Polypropylene or Vic-
ryl) (10%). Drains were left in place in 15 patients (19.7%),
6 of them affected by malignancy. The reasons were
marked perisplenic adhesions, perisplenic abscesses, and
intraoperative bleeding. Drains were removed in all pa-
tients within 48 hours. The spleen was extracted through
the umbilical port in case of an anterior approach and
through the left subcostal port in case of a semilateral
approach. An enlargement of the port site (3 cm to 4 cm)
was necessary in 3 patients. A Pfannenstiel incision was
used in 3 women (3.9%). To retrieve the spleen in 3 cases
of massive splenomegaly, the hand-assisted technique
was used, in 2 group II patients and 1 group I patient.
Twenty-eight patients had splenic ID 13 cm, and 35
patients had ID between 14 cm and 19 cm. Massive
splenomegaly (ID 20 cm) was noticed in 13 (17%) pa-
tients (mean ID, 234.1 cm). The operative time for these
last patients was 176.630.5 minutes with a mean hospital
stay of 6.63.9 days. Prevalence of massive splenomegaly
was registered in group II (9 patients), 8 of them with NHL
and one with hairy cell leukemia. Four patients from
group I had massive splenomegaly (pancytopenia, New-
man-Pick disease, autoimmune hemolytic anemia, and
Cooley disease).
Postoperative mortality was 1.3% (1 case in group II).
Blood transfusion was necessary in 4 patients (5.2%), 2
from each group.
The incidence of accessory spleen in ITP/spherocytosis
patients was 8.7% (2 of 23 patients). The accessory spleen
was localized at the splenic hilum (1.5 cm in diameter)
and in the great omentum (7 mm in diameter). Two other
cases of accessory spleen were registered in 2 patients
with NHL.
Histopathological results for group II are shown in
Table 4.
Postoperative Splenoportal Thrombosis
The incidence of postoperative thrombosis of the spleno-
portal branch was routinely examined in the last 41 pa-
tients undergoing LS. Partial thrombosis was registered in
4 (9.7%) of the 41 patients examined, 2 from group I
(3.8%) and 2 from group II (8.3%). Only 1 patient with
splenoportal thrombosis (group II) had massive spleno-
megaly. All patients were asymptomatic, and all received
low-weight molecular heparin 100 UI/kg twice for 45
days, with complete resolution at Doppler ultrasound ex-
aminations within 30 days.
Group I Outcomes (52 Patients)
Mean follow-up for benign diseases was 84 months
(range, 24 to 126). One HIV-positive patient with spleno-
megaly died 4 years after surgery. Two of 7 patients with
ITP did not have a significant increase in platelet count
(30000), even though scintigraphy excluded accessory
spleen. All other patients with ITP, spherocytosis, and
autoimmune hemolytic anemia are disease free. Patients
with beta-thalassemia had certain improvement, with a
delay in the interval between transfusions (from a mean of
11.1 days before intervention to 19.8 days after).
Group II Outcomes (24 Patients)
The mean follow-up was 54 months (range, 26 to 138).
Three patients were lost to follow-up. One patient with
acute myeloid leukemia died 60 days after surgery from
hepatic failure due to progression of the disease. Three
patients with NHD and 1 with HL died after a mean
interval of 13.2 months, and 2 patients with NHL died 71
months after LS for disease progression. At last follow-up,
14 patients were disease free, while 3 patients had recur-
rences and are being treated.
DISCUSSION
Laparoscopic splenectomy is generally accepted as a safe
procedure, and many authors consider LS the gold stan-
dard in the treatment of benign hematological diseases
with normal spleen size.8,11,16 Many retrospective studies
have demonstrated a reduction in postoperative pain,
hospital stay, and costs compared with a historical group
of open splenectomies, including adults and children with
ITP.4,17 Missing accessory spleens is reported as a down-
Table 4.
Histological Results in Group II (Malignant Diseases)
Histological Findings No.
Recurrence of lymphoma 14
Non-Hodgkin lymphoma 7
Hodgkin disease 1
Hair cells leukaemia 1
Myelofibrosis 1
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ever, even if studies with long-term follow-up are lacking,
LS seems to provide results similar to those of open sple-
nectomy in terms of identification of the accessory
spleens. Our results (8.3% in ITP, 5.2% in total) are com-
parable to the incidence described in larger series.9,18
The analysis of the present series of 76 consecutive LS,
performed in nonselected patients, confirms that the lapa-
roscopic approach is feasible and safe both in malignant
and benign hematological diseases. LS must be consid-
ered an advanced laparoscopic procedure with specific
pitfalls (ie, organ manipulation, specimen removal) be-
cause the spleen is a friable organ, with a close relation-
ship to other organs, such as the stomach, colon, and
pancreas. In addition, it must be removed intact for patho-
logical evaluation, in case malignant hematological disor-
ders are suspected. On the other hand, patients may
receive advantages from a laparoscopic approach, be-
cause these patients usually have co-morbidities.
LS can be carried out with very low morbidity and mor-
tality rates, comparable to or lower than those of open
splenectomy, after the learning curve period.19–21 In the
present study, LS was completed in 94.7% of cases (con-
version rate 5.3%) with an overall morbidity and mortality
of 7.9% and 1.3%, respectively. The conversion rate was
higher, although not statistically significant in cases of LS
performed for malignant versus benign diseases. Further-
more, in the last 57 patients, only 1 conversion was re-
quired (NHD with massive splenomegaly, ID 22 cm).
No intraoperative complications were recorded in patients
with splenomegaly. There was no significant difference in
the hospital stay between the 2 groups. Operative time
was longer in patients with malignant diseases than in
patients with benign conditions, without reaching a sta-
tistically significant difference. It could be in part justified
by the fact that subdiaphragmatic staging of lymphoma
requires liver and lymph node biopsies and, at the same
time, by the fact that spleen size was smaller in group I.
LS for massive splenomegaly and malignancy remains a
controversial issue.11,12,22–24 Spleen size is considered the
single most important condition affecting the conversion
rate, operative time, and complication rate.25 Some au-
thors12 consider massive splenomegaly as a relative con-
traindication to LS. Initial reports of LS in cases of spleno-
megaly showed higher operative complication rates and
led to lower acceptance of laparoscopy in these patients.
During the last few years, however, good results have
been reported even in the presence of splenomegaly.9,23
Standardization of the technique, increasing experience,
and technical innovations have shown that an enlarged
spleen can be managed successfully by laparoscopy. In a
previous report of 57 patients,26 the morbidity rate was
higher in lymphoma patients than in patients with benign
diseases. Standardization of the procedure has induced a
significant reduction in operative time, conversion and
complication rates.
Although one limit of the study is the different sample size
of the 2 groups (52 vs 24), the comparative analysis did
not show a significant statistical difference between ma-
lignant and benign diseases concerning conversion rate,
postoperative hospital stay, and morbidity. No differences
in morbidity were observed in patients with massive
splenomegaly versus those with a normal size spleen,
suggesting that splenomegaly is not a contraindication to
laparoscopy.
Initially, we adopted an anterior approach, because we
were more comfortable with it, especially during the
learning curve. Afterwards, we started using the semilat-
eral approach, which allows a quick dissection of the
splenic attachments and safe management of the splenic
hilum. In addition, in case of splenomegaly and malig-
nancy, with hilar adenopathy and perisplenitis, the lateral
or semilateral approach offers the advantages of gravity in
medial retraction of the organ and limits the amount of
tissue manipulation required.
During recent years in select cases, the hand-assisted
procedure has gained increasing acceptance.
27–29 We
adopted the hand-assisted technique in cases of massive
splenomegaly, following the evidence in the literature, for
nontraumatic handling of the spleen, a “finger control” of
bleeding, and rapid conversion if necessary.
30,31
Splenoportal thrombosis is a severe complication after
splenectomy, described both after open and laparoscopic
procedures,32,33 with an unknown true incidence.33 Early
recognition is of great importance for successful prompt
anticoagulant therapy.33,34 From December 1998, we de-
cided to apply a routine policy of ultrasound color Dopp-
ler examination of all patients undergoing LS to evaluate
the real incidence of the splenoportal thrombosis in our
patients. The incidence in the 41 patients studied was
9.7%, but all cases were asymptomatic. In this series, no
characteristics identified preoperatively by ultrasound
color Doppler of the splenic branches were correlated
with the development of postoperative intraportal throm-
bosis. Postoperative ultrasound color Doppler examina-
tion allowed an early diagnosis, suggesting that it should
be included in the routine postoperative management of
JSLS (2006)10:199–205 203LS for hematological diseases for an early diagnosis and
prompt initiation of anticoagulant therapy.
CONCLUSION
The results of the present study confirm that laparoscopy
should be considered the preferential approach for sple-
nectomy, even in patients with a diagnosis of malignant
disease and splenomegaly. In experienced centers, LS
may be considered safe and effective also in children with
benign or malignant hematological diseases. The present
series confirms that no specific condition can be consid-
ered an absolute contraindication to LS after the learning
curve period.
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